Kytopen Corp. is an MIT spin out founded in 2017 with core competencies in engineering biology, electrokinetics, and microfluidics. We are initially developing an automated cell engineering platform to accelerate discovery of bioengineered chemicals for societal needs such as biofuels, novel materials, and new therapeutics.
Paulo A. Garcia, Ph.D.CEO & Co-Founder
Dr. Paulo A. Garcia co-invented the Flowfect™ technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.
Cullen R. Buie, Ph.D.Co-Founder
Cullen R. Buie, Ph.D. is a Tenured Professor of Mechanical Engineering at MIT and co-inventor of the high-throughput genetic modification technology. He brings expertise in the areas of microfluidics, microfabrication, and experimental fluid mechanics to Kytopen.
James Hemphill, Ph.D.Research Scientist
James Hemphill, Ph.D. is a genetic engineer focused on building new functionality into human cells for therapeutic application. He received his Ph.D. in chemical biology from the University of Pittsburgh and has experience in platform development for adoptive cell therapy.
Jessica M. Sido, Ph.D.Research Scientist
Jessica M. Sido, Ph.D. graduated from the University of South Carolina School of Medicine where she worked on T cell driven inflammatory responses. She recently completed her postdoctoral research in cancer immunology at Harvard Medical School and Dana-Farber Cancer Institute.
Rameech McCormack, M.S.R&D Engineer
Rameech McCormack, M.S. master’s graduate from the Mechanical Engineering Department at MIT. He is also a co-inventor of the high throughput Flowfect™ technology. Rameech leads the effort in product manufacturing, design, and integration.
Kytopen is a technology company devoted to accelerating the development of genetically engineered cells. Leveraging technology developed at MIT, Kytopen can modify cells up to 10,000X faster than traditional methods. The technology enables continuous flow genetic manipulation of both eukaryotic and prokaryotic cells in a platform that can be easily automated through integration with liquid handling robots.